Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...

There are lots of misconceptions around eczema, from poor hygiene to the skin condition disappearing on its own - there is a ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

against rheumatoid arthritis and atopic dermatitis. AbbVie’s immunology treatments generate approximately 50% of total revenue, oncology products contribute about 30%, neuroscience adds roughly 10%, ...

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

So for long term treatment of allergies ... If we're talking about, kind of the flip side of this, which is the best long-term management of atopic dermatitis, as well as those JAK inhibitors work, ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth. Check out why I upgraded OGN ...